RE:$29 million vs $525 millionFirst off, while I agree that HEM is undervalued and has huge potential, but it is not really a fair comparison with SVA.
1. There's WAY more money in diabetes. More patients = more money.
2. Diabetes is cured by effective islet transplantation, which is what SVA is doing. We can already cure it in animals and have been able to do so for almost a decade.
3. There's HUGE money behind diabetes research which always accelerates research.
4. SVA has not had any legal battles.
Hemostemix future isn't quite as certain and the lawsuit and delaying the release of their midpoint data isn't helping clear up the fog.
Look, I'll be the first person to admit that I'm a small-time investor with limited knowledge. I invested in HEM because my partner has a PhD in Medical Science and she went looking specifically for a small innovative biotech company that we could invest in that had sound science behind it.
I have been trying to keep up to date with this company, but I believe that others like myself are still worried by HEM's legal problems... have they really "emerged from a legal cloud"? Is it actually over, or just likely to be over? Why haven't they released the midpoint data in the 30-45 day timeframe they set?
Ultimately I'm very excited about HEM's potential to make us all a lot of money.